Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14061238 | 0.87 | NPC1 (0.57) | NPC1RAB9ATP53SMN1; SMN2DYRK1A | |
| Hydrochloric Acid SCHEMBL6112989 | 0.85 | NPC1 (0.56) | NPC1RAB9ATP53SMN1; SMN2DYRK1A | |
| SCHEMBL29819602 | 0.85 | ALDH1A1 (0.53) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1869730 | 0.85 | FGFR1 (0.60) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL16602284 | 0.85 | ALDH1A1 (0.53) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL11171 | 0.83 | SMN1; SMN2 (0.50) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL3492748 | 0.81 | FGFR1 (0.53) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL29555125 | 0.81 | FGFR1 (0.53) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL12094844 | 0.81 | SMN1; SMN2 (0.48) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL10110841 | 0.81 | CHRNA7 (0.46) | CHRNA7NPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180362502-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218044-A2 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS INC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | CHRNA7 4382/4885NPC1 472/4885RAB9A 3490/4885 |
| US-20180362502-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | CHRNA7 4382/4885NPC1 472/4885RAB9A 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.